Sonnet BioTherapuetics(SONN)
Search documents
Sonnet BioTherapuetics(SONN) - 2022 Q4 - Annual Report
2022-12-15 21:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2932652 (State or Oth ...
Sonnet BioTherapuetics(SONN) - 2022 Q3 - Quarterly Report
2022-08-15 20:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Juris ...
Sonnet BioTherapuetics(SONN) - 2022 Q2 - Quarterly Report
2022-05-10 11:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2932652 ...
Sonnet BioTherapuetics(SONN) - 2022 Q1 - Quarterly Report
2022-02-08 11:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) Delaware 20-2932652 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-3557 ...
Sonnet BioTherapuetics(SONN) - 2021 Q4 - Annual Report
2021-12-17 01:44
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-2932652 (State or oth ...
Sonnet BioTherapuetics(SONN) - 2021 Q3 - Quarterly Report
2021-08-16 11:46
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in the charter) (State or other jurisdiction of ...
Sonnet BioTherapuetics(SONN) - 2021 Q2 - Quarterly Report
2021-05-17 12:30
Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in the charter) incorporation or organization) Identification Number) Delaware 20-2932652 (State or other jurisdiction of (I.R.S. Employer 100 Overlook Center, Suite 102, Princeton, NJ 0 ...
Sonnet BioTherapuetics(SONN) - 2021 Q1 - Quarterly Report
2021-02-16 12:57
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 Commission File Number 001-35570 SONNET BIOTHERAPEUTICS HOLDINGS, INC. Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, $0.0001 Par Value | SONN | The Nasdaq ...
Sonnet BioTherapuetics(SONN) - 2019 Q2 - Earnings Call Transcript
2019-08-15 02:57
Chanticleer Holdings, Inc. (BURG) Q2 2019 Results Earnings Conference Call August 15, 2019 4:30 PM ET Company Participants Jason Assad - Head of IR Michael Pruitt - Chairman and CEO Patrick Harkleroad - CFO Fred Glick - President Conference Call Participants David Burdick - Oak Ridge John O'Shea - Global Alliance Operator Welcome to the Chanticleer HoldingsÂ' Q2 2019 Conference Call. As a reminder, all participants are in a listen-only mode and the conference is being recorded. At this time, I would like to ...
Sonnet BioTherapuetics(SONN) - 2019 Q1 - Earnings Call Transcript
2019-05-15 23:00
Financial Data and Key Metrics Changes - Revenues increased by 2% to $10.2 million in Q1 2019 from $10 million in Q1 2018, driven by new store openings [17] - Overall operating loss improved by 28.3% to $1.7 million in Q1 2019 compared to an operating loss of $2.4 million in Q1 2018 [26] - Net loss attributable to common shareholders improved by 27.6% to $1.9 million in Q1 2019 from a net loss of $2.6 million in Q1 2018 [27] Business Line Data and Key Metrics Changes - Cost of sales as a percentage of restaurant sales improved to 33.1% in Q1 2019 from 33.5% in Q1 2018 [19] - Restaurant operating expenses increased to 63.1% in Q1 2019 compared to 55.9% in Q1 2018, driven by higher operating expenses for new stores [20] - Non-GAAP restaurant EBITDA was $560,000 in Q1 2019, down from $1.1 million in Q1 2018, attributed to the operating structure of new stores [26] Market Data and Key Metrics Changes - The company plans to open two new Little Big Burger locations in Seattle and one in Downtown Portland in the second half of 2019 [18] - Increased consumer demand for takeout and delivery services led to higher restaurant delivery expenses in Q1 [23] Company Strategy and Development Direction - The company announced a non-binding letter of intent for the acquisition of a Better Burger brand with reported revenues of $10 million per year and a store-level EBITDA of approximately 20% [10] - A corporate re-branding initiative is underway, including a name change to align with the new core ideology [13] - The company is focusing on enhancing profitability through partnerships with Food Service Industry Consultants and 7shifts to streamline operations and reduce costs [22][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's direction and the potential for improved financial performance and cash flow in the second half of 2019 [28] - The management team believes that the disconnect between the fundamental value of assets and the current share price presents an opportunity for growth [14] - The company anticipates measurable results from strategic initiatives in Q3 and Q4 2019 [31] Other Important Information - The company is investing in employee engagement and development to build loyalty and improve profitability [34] - A partnership with Beyond Meat is being established to create unique burger offerings [43] - The company is launching a loyalty platform in Q3 to enhance customer engagement and reduce delivery costs [41] Q&A Session Summary - No specific questions or answers were documented in the provided content.